Randomized, Open Label, Phase II Trial Comparing Rituximab Plus Sargramostim to Rituximab Monotherapy for the Treatment of Relapsed Follicular B-Cell Lymphoma.

Trial Profile

Randomized, Open Label, Phase II Trial Comparing Rituximab Plus Sargramostim to Rituximab Monotherapy for the Treatment of Relapsed Follicular B-Cell Lymphoma.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 24 Aug 2013

At a glance

  • Drugs Rituximab (Primary) ; Sargramostim (Primary)
  • Indications Follicular lymphoma
  • Focus Therapeutic Use
  • Acronyms PREMIER
  • Sponsors Bayer; Berlex Inc
  • Most Recent Events

    • 13 Apr 2010 'Genzyme Corporation' added as trial sponsor and affiliate as reported by ClinicalTrials.gov.
    • 13 Apr 2010 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
    • 30 Jun 2009 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top